We are live on ! Find out more
PAI

ProQuest Associates IV Portfolio holdings

AUM $53M
1-Year Est. Return 3.35%
This Fund
S&P 500
This Quarter Est. Return
+2.95%
1 Year Est. Return
+3.35%
3 Year Est. Return
+113.14%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$333M
AUM Growth
-$20.7M
Cap. Flow
-$22.3M
Cap. Flow %
-6.7%
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$22.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EGRX
1
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$303M 91.1%
3,652,284
-299,794
-8% -$22.3M
AGRX
2
DELISTED
Agile Therapeutics
AGRX
$16.3M 4.89%
2,531
– –
IMDZ
3
DELISTED
Immune Design Corp.
IMDZ
$13.3M 4.01%
1,962,720
– –

Similar funds

CCP
Centaur Capital Partners Southlake, Texas $54.1M AUM 12.4% 1-Year Est. Return
CLA
Cranberry Lake Advisors Houston, Texas $50.6M AUM 5.12% 1-Year Est. Return
HC
Hampstead Capital London, United Kingdom $55.8M AUM 2.76% 1-Year Est. Return
SF
Schooner Foundation Boston, Massachusetts $49.6M AUM 9.4% 1-Year Est. Return
DIV
DCM International V Menlo Park, California $47.8M AUM 19.52% 1-Year Est. Return
MGPI
Maveron General Partner III Seattle, Washington $46.7M AUM 35.29% 1-Year Est. Return
MCAI
Meritech Capital Associates III Palo Alto, California $45.8M AUM 24.9% 1-Year Est. Return
P
PhaseCapital New York $45.2M AUM 8.85% 1-Year Est. Return

ProQuest Associates IV's Q1 2017 Portfolio in Review

As of Q1 2017, ProQuest Associates IV held 3 positions worth $333M, down 5.9% from $353M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ProQuest Associates IV withdrew a net $22.3M in Q1 2017, reducing 1 holding. Its largest reduction was Eagle Pharmaceuticals, Inc., cutting an estimated $22.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ProQuest Associates IV's biggest Q1 2017 reduction was Eagle Pharmaceuticals, Inc., cutting an estimated $22.3M.
  • ProQuest Associates IV's ten largest holdings make up 100% of its $333M portfolio in Q1 2017.
  • ProQuest Associates IV opened 0 new positions and closed 0 in Q1 2017.
  • ProQuest Associates IV's portfolio value fell 5.9% quarter-over-quarter to $333M.

Based on ProQuest Associates IV's 13F filing for Q1 2017, filed 15 May 2017.